HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate FDA Appropriations Rival House, But Partisan Roadblock Looms

This article was originally published in The Rose Sheet

Executive Summary

Senate and House bills propose $2.552 billion and $2.485 billion in direct appropriations for FDA in fiscal 2014, but partisan battles in Congress make a continuing resolution to start fiscal 2014 seem inevitable.

You may also be interested in...

FDA User Fee Liberation Likely Hinges On Senate Appropriations Panel

House leadership plans a comprehensive bill to undo sequestration for the government as a whole, but Republican Robert Aderholt, who chairs the House subcommittee that originates appropriations for FDA, says he is willing to work with Senate appropriators in conference on a fix specific to the agency’s user fees.

Pink Sheet Podcast: Understanding the White House Coronavirus Treatment Announcement, US FDA Postpones Domestic Inspections, Biologics Transition Day Arrives

Pink Sheet editor and reporters discuss the pending trials of chloroquine for use against coronavirus, expanded access for remdesivir, and the official move of several biologics from regulation as drugs to regulation as biologics. 

Pink Sheet Podcast: US FDA Announces Coronavirus Containment Strategy, Issues Updated Type 2 Diabetes Guidance

Pink Sheet reporter and editor consider the fall-out from the FDA decision to cancel meetings and postpone inspections due to the coronavirus pandemic, as well as look at the new cardiovascular recommendations for Type 2 diabetes drug development.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts